Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo

Cell Cycle

Volumn 9, Issue 8, 2010, Pages 1590-1600

  Hirai, Hiroshi ^a   Shimomura, Toshiyasu ^a   Kobayashi, Makiko ^a   Eguchi, Tomohiro ^a   Taniguchi, Eri ^a   Fukasawa, Kazuhiro ^a   Machida, Takumitsu ^a   Oki, Hiroko ^a   Arai, Tsuyoshi ^a   Ichikawa, Koji ^a   Hasako, Shinichi ^a   Haze, Kyosuke ^a   Kodera, Tsutomu ^a   Kawanishi, Nobuhiko ^a   Takahashi Suziki, Ikuko ^a   Nakatsuru, Yoko ^a   Kotani, Hidehito ^a   Iwasawa, Yoshikazu ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cdk; Cdk4 6 selective inhibitor; Small molecule inhibitor

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PARAMETERS; CELL PROLIFERATION; CONTROLLED STUDY; CRYPT CELL; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXPERIMENTAL NEOPLASM; GENETIC TRANSCRIPTION; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPHOMA CELL; MALE; NONHUMAN; RAT; TUMOR XENOGRAFT;

RATTUS;

EID: 77953553524     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.8.11306     Document Type: Article

References (44)

1. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-7.
2. Sherr CJ. The Pezcoller lecture: cancer cell cycles revised. Cancer Res 2000; 60:3689-95.
3. Pines J. Cyclins ands cyclin-dependent kinases: theme and variations. Adv Cancer Res 1995; 66:181-212.
4. Pavletich NP. Mechanism of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and CIP and INK4 inhibitors. J Mol Biol 1999; 287:821-8.
5. Koepp DM, Haper JW, Elledge SJ. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999; 97:431-4.
6. Dyson N. The regulation of E2F by pRb-family proteins. Genes Dev 1998; 12:2245-62.
7. Zheng L, Lee WH. The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. Exp Cell Res 2001; 264:2-18. (Pubitemid 32989077)
8. 1-phase progression. Genes Dev 1999; 13:1501-12.
9. Shapiro GI, Harper JW. Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 1999; 104:1645-53.
10. Steiner MS, Zhang Y, Farooq F, Lerner J, Wang Y, Lu Y. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther 2000; 7:360-72. (Pubitemid 30210403)
11. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999; 18:5311-7.
12. Carnero A. Targeting the cell cycle for cancer therapy. Br J Cancer 2002; 87:129-33.
13. Elsayed YA, Sausville EA. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist 2001; 6:517-37.
14. Hirai H, Kawanishi N, Iwasawa Y. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Frontiers in Medicinal Chemistry 2009; 4:347-70. (Pubitemid 40514513)
15. Dickson MA, Schwartz GK. Development of cell cycle inhibitors for cancer therapy. Curr Oncol 2009; 16:36-43.
16. Shimamura T, Shibata J, Kurihara H, Mita T, Otsuki S, Sagara T, et al. Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7 and 9. Bioorg Med Chem Lett 2006; 16:3751-4.
17. Yan Z, DeGregori J, Shohet R, Leone G, Stillman B, Nevins JR, Williams RS. Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci USA 1998; 95:3603-8. (Pubitemid 28173174)
18. Hateboer G, Wobst A, Petersen BO, Le Cam L, Vigo E, Sardet C, et al. Cell cycle-regulated expression of mammalian CDC6 is dependent on E2F. Mol Cell Biol 1998; 18:6679-97. (Pubitemid 28500556)
19. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, et al. Retinoblastoma-protein-dependent cell cycle inhibition by the tumour suppressor p16. Nature 1995; 375:503-6.
20. INK4B/MTS2- related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994; 8:2939-52.
21. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995 92:6289-93.
22. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430:226-31. (Pubitemid 38902433)
23. Liu F, Matsuura I. Inhibition of Smad antiproliferative function by CDK phosphorylation. Cell Cycle 2005; 4:63-6. (Pubitemid 41038929)
24. Malumbres M, Sotillo R, Santamaría D, Galan J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004; 118:493-504. (Pubitemid 39485668)
25. Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992; 71:505-14.
26. Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene 1997; 14:1329-40. (Pubitemid 27151990)
27. Kip1 activity. Mol Cell Biol 1999; 19:7011-9.
28. 1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006; 66:7661-7.
29. Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 2007; 110:2075-83. (Pubitemid 47443925)
30. Fry DW, Bedford DC, Harvey PH, Fritsch PR, Keller PR, Wu Z, et al. Cell cycle and biochemical effects of PD 0183812. J Biol Chem 2001; 276:16617-23.
31. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427-37. (Pubitemid 39562588)
32. Xiong Y, Zhang H, Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993; 7:1572-83. (Pubitemid 23234350)
33. Bates S, Parry D, Bonetta L, Vousden K, Dickson C, Peters G. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene 1994; 9:1633-40. (Pubitemid 24163389)
34. 1 progression. Oncogene 1994; 9:2663-74.
35. Hirai H, Takahashi-Suzuki I, Shimomura T, Fukasawa K, Machida T, Takaki T, et al. Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo. Invest New Drugs 2010; In press.
36. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998; 91:2482-90 (Pubitemid 28155524)
37. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92:376-87.
38. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399-404. (Pubitemid 46105932)
39. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, et al. Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113:2637-45.
40. Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004; 22:315-22. (Pubitemid 39012571)
41. Grendys EC Jr, Blessing JA, Burger R, Hoffman J. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2005; 98:249-53.
42. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, et al. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase II trial with clinical and pharmacodynamic end-points. Haematologica 2006; 91:390-3.
43. Benson C, White J, De Bono J, O'Donnell A, Raunaud F, Cruickshank C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007; 96:29-37.
44. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase I study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008; 26:59-65.